Related Experiment Video

Updated: Oct 9, 2026

Mouse Models Of Helicobacter Infection And Gastric Pathologies
07:43

Mouse Models Of Helicobacter Infection And Gastric Pathologies

Published on: October 18, 2018

Review article: infective complications of therapeutic gastric acid inhibition

A J Larner1, M I Hamilton

  • 1University of Cambridge Department of Anatomy, Royal Free Hospital, London, UK.

Alimentary Pharmacology & Therapeutics
|December 1, 1994
PubMed

Insights

Therapeutic inhibition of gastric acid secretion may increase the risk of certain infections, such as salmonellosis and campylobacter infections. Other gastrointestinal defense mechanisms may also need to be impaired for infection to occur.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Pharmacology

Background:

  • Gastric acid secretion acts as a natural defense against microbial invasion of the gastrointestinal tract.
  • Medications that inhibit gastric acid, like histamine H2 receptor antagonists and proton pump inhibitors, may compromise this protective barrier.

Purpose of the Study:

  • To review clinical reports of infections associated with therapeutic gastric acid inhibition.
  • To assess the infection risk posed by treatments that reduce stomach acid production.

Main Methods:

  • Literature review of clinical reports.
  • Analysis of infection incidence during acid-inhibitory therapy.

Main Results:

  • Increased prevalence of non-typhoid salmonelloses and Campylobacter infections observed.
  • Potential increased risk of local candidiasis and Strongyloides hyperinfections noted.
  • Infection may require concurrent impairment of other gastrointestinal defenses.

Conclusions:

  • Therapeutic gastric acid inhibition may predispose individuals to specific infections.
  • The risk is likely influenced by the type of pathogen and the integrity of other host defense mechanisms.

More Related Videos

Profiling Luminal pH in Three-Dimensional Gastrointestinal Organoids Using Microelectrodes08:24

Profiling Luminal pH in Three-Dimensional Gastrointestinal Organoids Using Microelectrodes

Published on: July 5, 2024

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...